Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Find out why I'm bullish on PFE stock.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its ...

This historical pattern reflects 10 out of 23, or only a 43% chance of a rise in PFE stock over the coming month. See our analysis on Pfizer Stock Chances of Rise for more details.

Pfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis ...